CSPC Jushi Biopharmaceutical

CSPC Jushi Biopharmaceutical is a specialized subsidiary of CSPC Pharmaceutical Group focused on the research, development, and commercialization of innovative biologics. The company maintains a robust portfolio centered on antibody-drug conjugates (ADCs), monoclonal antibodies, and mRNA-based vaccines and therapeutics. Notably, CSPC Jushi developed China's first domestically developed mRNA COVID-19 vaccine to receive emergency use authorization. The company leverages advanced technology platforms to target high-unmet-need areas in oncology, infectious diseases, and inflammatory conditions. With multiple programs in late-stage clinical trials and strategic out-licensing deals with global partners, CSPC Jushi is a key player in the Chinese biotechnology landscape.